Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Catalent, Inc.

NYSE

Market Cap.

9.92B

Avg. Volume

1.83M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Catalent, Inc.!

Still processing it, give me a bit more time...

Catalent, Inc. News

Catalent, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareDrug Manufacturers - Specialty & Generic
catalent.com

About Catalent, Inc.

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent, Inc. Earnings & Revenue

Catalent, Inc. Financials

Table Compare

Compare CTLT metrics with:

   

Earnings & Growth

CTLT

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

CTLT

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

CTLT

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

CTLT

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Catalent, Inc. Income

Catalent, Inc. Balance Sheet

Catalent, Inc. Cash Flow

Catalent, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquitySell
Return on AssetsNeutral
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Catalent, Inc. Executives

NameRole
Mr. Alessandro MaselliPresident, Chief Executive Officer & Director
Dr. Aristippos Gennadios Ph.D.Group President of Pharma & Consumer Health Segment
Mr. Ricky HopsonPresident, Division Head for BioProduct Delivery & Chief of Staff
Mr. John J. Greisch M.B.A.Executive Chairman of the Board
Mr. Joseph A. Ferraro J.D.Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary
NameRoleGenderDate of BirthPay
Mr. Alessandro MaselliPresident, Chief Executive Officer & DirectorMale19721.08M
Dr. Aristippos Gennadios Ph.D.Group President of Pharma & Consumer Health Segment1966799.26K
Mr. Ricky HopsonPresident, Division Head for BioProduct Delivery & Chief of StaffMale1977622.13K
Mr. John J. Greisch M.B.A.Executive Chairman of the BoardMale1955125.91K
Mr. Joseph A. Ferraro J.D.Senior Vice President, General Counsel, Chief Compliance Officer & Corporate SecretaryMale1978

--

Catalent, Inc. Insider Trades

Date15 Mar
NameGunther Scott
RoleSVP, Quality & Reg. Affairs
TransactionDisposed
TypeS-Sale
Shares387
Date25 Jan
NameKreuzburg Christa
RoleDirector
TransactionDisposed
TypeF-InKind
Shares523
Date16 Jan
NameHatzfeld Michael
RoleChief Accounting Officer
TransactionAcquired
TypeA-Award
Shares1837
Date16 Jan
NameHatzfeld Michael
RoleChief Accounting Officer
TransactionAcquired
TypeA-Award
Shares6071
Date16 Jan
NameHatzfeld Michael
RoleChief Accounting Officer
TransactionAcquired
TypeA-Award
Shares3981
DateNameRoleTransactionTypeShares
15 MarGunther ScottSVP, Quality & Reg. AffairsDisposedS-Sale387
25 JanKreuzburg ChristaDirectorDisposedF-InKind523
16 JanHatzfeld MichaelChief Accounting OfficerAcquiredA-Award1837
16 JanHatzfeld MichaelChief Accounting OfficerAcquiredA-Award6071
16 JanHatzfeld MichaelChief Accounting OfficerAcquiredA-Award3981

Discover More

Streamlined Academy

Catalent, Inc.

NYSE

Market Cap.

9.92B

Avg. Volume

1.83M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Catalent, Inc. News

Catalent, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Catalent, Inc. Earnings & Revenue

Catalent, Inc. Income

Catalent, Inc. Balance Sheet

Catalent, Inc. Cash Flow

Catalent, Inc. Financials Over Time

Catalent, Inc. Executives

NameRole
Mr. Alessandro MaselliPresident, Chief Executive Officer & Director
Dr. Aristippos Gennadios Ph.D.Group President of Pharma & Consumer Health Segment
Mr. Ricky HopsonPresident, Division Head for BioProduct Delivery & Chief of Staff
Mr. John J. Greisch M.B.A.Executive Chairman of the Board
Mr. Joseph A. Ferraro J.D.Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary
NameRoleGenderDate of BirthPay
Mr. Alessandro MaselliPresident, Chief Executive Officer & DirectorMale19721.08M
Dr. Aristippos Gennadios Ph.D.Group President of Pharma & Consumer Health Segment1966799.26K
Mr. Ricky HopsonPresident, Division Head for BioProduct Delivery & Chief of StaffMale1977622.13K
Mr. John J. Greisch M.B.A.Executive Chairman of the BoardMale1955125.91K
Mr. Joseph A. Ferraro J.D.Senior Vice President, General Counsel, Chief Compliance Officer & Corporate SecretaryMale1978

--

Catalent, Inc. Insider Trades

Date15 Mar
NameGunther Scott
RoleSVP, Quality & Reg. Affairs
TransactionDisposed
TypeS-Sale
Shares387
Date25 Jan
NameKreuzburg Christa
RoleDirector
TransactionDisposed
TypeF-InKind
Shares523
Date16 Jan
NameHatzfeld Michael
RoleChief Accounting Officer
TransactionAcquired
TypeA-Award
Shares1837
Date16 Jan
NameHatzfeld Michael
RoleChief Accounting Officer
TransactionAcquired
TypeA-Award
Shares6071
Date16 Jan
NameHatzfeld Michael
RoleChief Accounting Officer
TransactionAcquired
TypeA-Award
Shares3981
DateNameRoleTransactionTypeShares
15 MarGunther ScottSVP, Quality & Reg. AffairsDisposedS-Sale387
25 JanKreuzburg ChristaDirectorDisposedF-InKind523
16 JanHatzfeld MichaelChief Accounting OfficerAcquiredA-Award1837
16 JanHatzfeld MichaelChief Accounting OfficerAcquiredA-Award6071
16 JanHatzfeld MichaelChief Accounting OfficerAcquiredA-Award3981

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - Specialty & Generic
catalent.com

About Catalent, Inc.

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Catalent, Inc.!

Still processing it, give me a bit more time...

Catalent, Inc. Financials

Table Compare

Compare CTLT metrics with:

   

Earnings & Growth

CTLT

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

CTLT

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

CTLT

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

CTLT

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Catalent, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquitySell
Return on AssetsNeutral
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More